YIH
IKT icon

Y-Intercept (HK)’s Inhibikase Therapeutics IKT Stock Holding History

Y-Intercept (HK)’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,775
Closed -$58.6K – 1805
2025
Q1 		$58.6K Buy
+26,775
New +$67.3K ﹤0.01% 1126

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Y-Intercept (HK)'s IKT Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Inhibikase Therapeutics (IKT) in Q2 2025, closing a stake of 26,775 shares — an estimated $58.6K sold.

Y-Intercept (HK) first reported a position in IKT in Q1 2025 and held it in 1 quarter. The position peaked at $58.6K in Q1 2025. 48 funds tracked by Wall St. Rank hold IKT as of Q2 2025.

  • Y-Intercept (HK) reported no remaining Inhibikase Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 26,775 Inhibikase Therapeutics shares in Q2 2025, an estimated $58.6K.
  • Y-Intercept (HK) first reported a position in Inhibikase Therapeutics in Q1 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Inhibikase Therapeutics position peaked at $58.6K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.